Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
about
Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and RehabilitationWhat can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesLRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesiasThe Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity.Auditory- and Vestibular-Evoked Potentials Correlate with Motor and Non-Motor Features of Parkinson's Disease.Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's DiseaseNeuronal firing patterns outweigh circuitry oscillations in parkinsonian motor controlChemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaGBA Variants Influence Motor and Non-Motor Features of Parkinson's Disease.Complete Comparison Display (CCD) evaluation of ethanol extracts of Centella asiatica and Withania somnifera shows that they can non-synergistically ameliorate biochemical and behavioural damages in MPTP induced Parkinson's model of miceAn updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease.Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.Opioid system in L-DOPA-induced dyskinesia.Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.G protein-coupled receptor kinases as regulators of dopamine receptor functions.Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Repairing the Aged Parkinsonian Striatum: Lessons from the Lab and Clinic.l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?Non-human primate models of PD to test novel therapies.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Evaluation of an Arabic version of the non-motor symptoms scale in Parkinson's disease.The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.Mechanisms for pattern specificity of deep-brain stimulation in Parkinson's disease.Biomarker Research in Parkinson's Disease Using Metabolite Profiling.Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical ImplicationsDopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian MicePET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity.Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death.
P2860
Q26745654-69BEA8C3-4102-44F3-9845-8A5616394AB2Q26767268-E15C8DDC-423F-459E-88E7-042632BA58A2Q28066691-D20714A7-7634-4E9A-A528-6F6B3A57DC0AQ28602836-6323122E-78A7-4CA9-8125-798A4D1B2825Q30357944-3E8AB2DA-F097-4524-B187-6C11F30A2238Q30361239-72C6ABA0-085B-42D0-BC84-AD010C5D7792Q30383888-22B53611-8E25-49AA-94B7-2ADAB38379A8Q30830175-2FB8B0FA-8098-4D16-81FC-1829CD399640Q30836713-31BE8952-0240-4370-AE60-66DFC2F0608AQ33725654-062979A7-2B24-4077-B07C-0863AA04F9A7Q36234536-B2EFD436-594D-4354-B77D-7C6A1892D2ADQ36373173-140833C5-3853-431B-91F1-AD54FF3E7957Q36376607-05E981B2-C1FF-491D-9F92-59128E92241AQ36563103-E23795F0-8695-4BD6-BB49-2B2B745A7BB7Q37241737-D690213A-4BD8-487B-BFF1-C0EE8D6DF353Q37348980-1BBBA9C9-4E22-4982-BAAF-E9CBC4ADD157Q37589209-1BBB2249-3377-4C95-9A69-DD779BE2FF2AQ37644775-70F454AD-18F9-4B98-A867-AB828F1A6D65Q38629277-5ED705B2-DD1F-44B8-AC4B-E061D30194A2Q38719357-5BBA5DD0-E4B1-4C95-A76F-ABBCA99EFEB8Q38811387-4131832A-E131-41EF-B243-04704CE1FF5BQ38834292-15F5FA21-CC54-4AB9-8881-4ADFFB2A3663Q38931640-068D0916-3A6C-40B4-824D-D6C856966001Q38937893-FC7F61DF-DB86-4927-B11C-33A75B2E8B9CQ38951947-E6D4F0A6-C3B5-442C-8A97-BDEB5B06AEDFQ39006312-9B7E881E-5B24-4D13-99F7-B9D3E6566D48Q39012371-A5CA0ACA-B4D7-4AB4-B7AC-FFE2150A27BAQ39229450-2121FE5E-9A44-4CFF-A50B-8BC9E35D6375Q39324877-28282753-9E3E-4372-9950-2232F9D00EBBQ39438767-ADB65928-DAC9-468C-B31D-FE5151B7EE24Q39445082-C8132965-ECA0-411D-890C-D06D8ACE4EFBQ39604782-EA33EEFF-91A6-432D-AB04-C10114A75BCBQ41433072-E7ABBA0C-9F10-4267-94A4-AD49828AAE9BQ41666702-0BDB09C3-CCB8-4849-887C-74D9F33FB94FQ41684008-4FCFFB99-19AA-4A24-8093-ADE43FE9AC52Q42322627-0F6B0CCA-4200-40EE-9700-DE6AA5A42AA0Q42369736-8FD2EF1E-BA97-495C-8C67-EA186759625AQ42502750-E39E42EF-509A-4230-8712-E1BAF4705DFDQ42532569-DDBA054E-8207-4C11-9147-DC06E9887D7CQ46323541-384E0830-8CE2-4912-9320-6010A6946595
P2860
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pathophysiology of L-dopa-indu ...... ations in Parkinson's disease.
@en
type
label
Pathophysiology of L-dopa-indu ...... ations in Parkinson's disease.
@en
prefLabel
Pathophysiology of L-dopa-indu ...... ations in Parkinson's disease.
@en
P2093
P50
P1476
Pathophysiology of L-dopa-indu ...... ations in Parkinson's disease.
@en
P2093
Alan R Crossman
Dominique Guehl
Elisabetta Tronci
Eugenia V Gurevich
Fabrizio Gardoni
François Tison
Gilberto Fisone
Laurent Groc
M Angela Cenci
Maria-Cruz Rodriguez
P304
P356
10.1016/J.PNEUROBIO.2015.07.002
P50
P577
2015-07-21T00:00:00Z